Innovation

Jordan Schecter, M.D., leader of Johnson & Johnson’s end-to-end development strategy for multiple myeloma, shares insight on the evolving treatment landscape of this rare blood cancer.

Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.

This pro-inflammatory protein is the target of potential Johnson & Johnson medications that could help treat immune-mediated diseases such as psoriasis, inflammatory bowel disease and rheumatoid arthritis.

Expertise, innovation and insight are fueling the development of remote and AI-powered approaches to healthcare—potentially improving treatment decisions and evolving the way clinical trials are designed and managed.

Cell therapy is bringing the world one step closer to eliminating cancer. Here’s how Johnson & Johnson has treated more than 10,000 patients and counting with this cutting-edge therapy.

Kimberly Lounds Foster, Soumya D. Chakravarty and Carmen Canovas Vidal are part of a new wave of innovators bringing their expertise in STEM into the heart of healthcare.

It may look deceptively simple, but this tool can help stop patients from bleeding during surgery.

Experts aren’t sure why, but sometimes changes in DNA can trigger cancer to grow and spread. Learn all about gene mutations—and Johnson & Johnson’s work developing new therapies to target these specific types of cancer.

Johnson & Johnson’s Leonardo Diaz, M.D., addresses common misconceptions about schizophrenia, the critical importance of preventing relapse and why there’s so much optimism about treatments.

Cataracts are the most common cause of vision loss worldwide. Luckily a routine surgical procedure can have you viewing the world in crisp, bright color again. Here’s what to know about cataract symptoms and removal.